尿激酶联合肝素静脉溶栓治疗急性心肌梗死的临床疗效观察

目的探讨尿激酶联合肝素静脉溶栓治疗急性心肌梗死的疗效价值。方法选取我院符合急性心肌梗死溶栓标准的患者66例，分为实验组和对照组各33例。实验组于溶栓前给予低分子肝素5000U静推，随后两组均给予尿激酶150万U加入100mL0．9％氯化钠溶液中，于30min内静脉输注溶栓。结果两组CK、CK—NB水平较治疗前明显下降，但实验组明显低于同期对照组治疗水平。实验组总有效率84．85％高于对照组72．73％，两组差异有统计学意义（P〈O．05）。结论尿激酶联用低分子肝素静脉溶栓治疗急性心肌梗死的方法安全有效，应用较方便，值得在临床推广。

The clinical efficiency study of urokinaes and heparin intravenous thrombolytic therapy for acute myocardial infarction

Objective To study the value of the intravenous thrombolysis with urokinase and heparin treatment for acute myocardial infarction.Methods All 66 cases of acute myocardial infarction were divided into the experimental group and the control group.Before given thrombolytic therapy,the experimental group was given 5000 U heparin bolus.Then 1500 000 U of urokinase were given in two groups by adding 100 mL normal saline in 30 minutes intravenous infusion thrombolysis.Results CK,CK-MB levels in both groups decreased,which was lower in the experimental group than the level in the control group.The experimental group owned a total effective rate of 84.85%,higher than that of the control group 72.73%.All difference was statistically significant(P<0.05).Conclusion It is safe and efficient to use urokinaes and LMWH for intravenous thrombolytic therapy in patients with AMI,which deserves to be popularized in practice.